Eptifibatide
Also referenced as: Integrilin
A cyclic heptapeptide antiplatelet medicine used in selected acute coronary and procedural care.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved for acute coronary syndrome and PCI, including stenting, under product-specific label criteria.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A cyclic heptapeptide antiplatelet medicine used in selected acute coronary and procedural care.
FDA-approved for acute coronary syndrome and PCI, including stenting, under product-specific label criteria.
Its risk-benefit balance belongs to acute clinical care, not routine cardiovascular prevention.
Why It's Being Studied
- Acute coronary syndrome
- PCI
- Platelet aggregation
Mechanism of Action
Platelet glycoprotein IIb/IIIa antagonism inhibits fibrinogen-mediated platelet aggregation.
Platelet glycoprotein IIb/IIIa antagonism inhibits fibrinogen-mediated platelet aggregation. Its risk-benefit balance belongs to acute clinical care, not routine cardiovascular prevention.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Acute coronary syndrome
- PCI
- Platelet aggregation
- Intravenous approved medicine
Evidence Summary
Human clinical evidence supports reduction of ischemic events in selected ACS and PCI contexts.
Higher tiers carry more weight. Filled tiers have evidence for Eptifibatide; tap to read it.
- Human clinical evidence supports reduction of ischemic events in selected ACS and PCI contexts.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human clinical evidence supports reduction of ischemic events in selected ACS and PCI contexts.
Reported Adverse Events in Research
- Serious bleeding and thrombocytopenia are key risks; dialysis dependence is a contraindication.
Limitations of Current Evidence
- Its risk-benefit balance belongs to acute clinical care, not routine cardiovascular prevention.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Eptifibatide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Eptifibatide — prescribing label